327 related articles for article (PubMed ID: 7865899)
1. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.
Weidner DA; Busch H
Oncol Res; 1994; 6(6):237-42. PubMed ID: 7865899
[TBL] [Abstract][Full Text] [Related]
2. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao WY; Han FS; Storm C; Egan W; Cheng YC
Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
[TBL] [Abstract][Full Text] [Related]
3. Phosphorothioate oligonucleotides block reverse transcription by the Rnase H activity associated with the HIV-1 polymerase.
Hatta T; Takai K; Yokoyama S; Nakashima H; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1995 Jun; 211(3):1041-6. PubMed ID: 7541196
[TBL] [Abstract][Full Text] [Related]
4. Selective binding of trisamine-modified phosphorothioate antisense DNA to target mRNA improves antisense activity and reduces toxicity.
Matsukura M; Okamoto T; Miike T; Sawai H; Shinozuka K
Biochem Biophys Res Commun; 2002 May; 293(5):1341-7. PubMed ID: 12054660
[TBL] [Abstract][Full Text] [Related]
5. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids.
Lima WF; Crooke ST
Biochemistry; 1997 Jan; 36(2):390-8. PubMed ID: 9003192
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression.
Perlaky L; Saijo Y; Busch RK; Bennett CF; Mirabelli CK; Crooke ST; Busch H
Anticancer Drug Des; 1993 Feb; 8(1):3-14. PubMed ID: 8476501
[TBL] [Abstract][Full Text] [Related]
7. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466.
Saijo Y; Perlaky L; Valdez BC; Wang H; Henning D; Busch H
Oncol Res; 1993; 5(8):283-91. PubMed ID: 8012060
[TBL] [Abstract][Full Text] [Related]
8. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells.
Hatta T; Takai K; Nakada S; Yokota T; Takaku H
Biochem Biophys Res Commun; 1997 Mar; 232(2):545-9. PubMed ID: 9125219
[TBL] [Abstract][Full Text] [Related]
10. Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity.
Giles RV; Spiller DG; Tidd DM
Anticancer Drug Des; 1993 Feb; 8(1):33-51. PubMed ID: 8386514
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bacterial RNase P RNA as a drug target.
Willkomm DK; Gruegelsiepe H; Goudinakis O; Kretschmer-Kazemi Far R; Bald R; Erdmann VA; Hartmann RK
Chembiochem; 2003 Oct; 4(10):1041-8. PubMed ID: 14523922
[TBL] [Abstract][Full Text] [Related]
12. Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides.
Hasselblatt P; Hockenjos B; Thoma C; Blum HE; Offensperger WB
Nucleic Acids Res; 2005; 33(1):114-25. PubMed ID: 15640448
[TBL] [Abstract][Full Text] [Related]
13. Similarities and differences in the RNase H activities of human immunodeficiency virus type 1 reverse transcriptase and Moloney murine leukemia virus reverse transcriptase.
Gao HQ; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 1999 Dec; 294(5):1097-113. PubMed ID: 10600369
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
Alahari SK; Dean NM; Fisher MH; Delong R; Manoharan M; Tivel KL; Juliano RL
Mol Pharmacol; 1996 Oct; 50(4):808-19. PubMed ID: 8863825
[TBL] [Abstract][Full Text] [Related]
15. Phosphorothioate-phosphodiester oligonucleotide co-polymers: assessment for antisense application.
Ghosh MK; Ghosh K; Cohen JS
Anticancer Drug Des; 1993 Feb; 8(1):15-32. PubMed ID: 8386513
[TBL] [Abstract][Full Text] [Related]
16. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
Kronenwett R; Haas R; Sczakiel G
J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
[TBL] [Abstract][Full Text] [Related]
17. RNase H1 can catalyze RNA/DNA hybrid formation and cleavage with stable hairpin or duplex DNA oligomers.
Li J; Wartell RM
Biochemistry; 1998 Apr; 37(15):5154-61. PubMed ID: 9548746
[TBL] [Abstract][Full Text] [Related]
18. Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems.
Ghosh MK; Ghosh K; Cohen JS
Antisense Res Dev; 1992; 2(2):111-8. PubMed ID: 1327332
[TBL] [Abstract][Full Text] [Related]
19. Antisense inhibition of Escherichia coli RNase P RNA: mechanistic aspects.
Gruegelsiepe H; Willkomm DK; Goudinakis O; Hartmann RK
Chembiochem; 2003 Oct; 4(10):1049-56. PubMed ID: 14523923
[TBL] [Abstract][Full Text] [Related]
20. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
